Designing Growth Strategies is in our DNA

Glioblastoma Drugs Market Size, Share & Industry Analysis, By Drug (Temozolomide, Bevacizumab, Carmustine, Lomustine, Procarbazine, and Others), By Drug Class (Alkylating Agents, VEGF/Angiogenesis Inhibitors, Nitrosoureas, Platinum Compounds, Topoisomerase Inhibitors, and Others), By Age Group (Pediatric and Adults), By Type (Branded and Generic), By Therapy (Targeted Therapy, Immunotherapy, Chemotherapy, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Others), and Regional Forecast, 2026-2034

Last Updated :July 17, 2026 | Format:PDF | Report ID: 116045

 

Request for Customization

man icon
Mail icon
Mail icon
Get 30-60 Hours of FREE Customization on this Report
Company Mapping:

Additional company profiling and benchmarking

Competitive Intelligence:

Advanced competitive landscape assessment

Segment Broadening:

Expanded segment-level coverage

Use-Case Analysis:

Tailored application and end-user evaluation

Extended Study Period:

Extended forecast and historical period

Geographic Granularity:

More detailed regional and country-level insights

Companies Who Rely On Us For Their Market Research Needs
3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
  • 2021-2034
  • 2025
  • 2021-2024
  • 190